Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited) has received final approval from the United States Food and Drug Administration (USFDA) to market Acetaminophen Injection, 1,000 mg/100 mL (10 mg/mL) single-dose vials (USRLD: Ofirmev®).
Acetaminophen injection is indicated to relieve mild to moderate pain and to reduce fever. It is also used in combination with opioid (narcotic) medications to relieve moderate to severe pain. The drug will be manufactured at the group's injectable manufacturing facility at Jarod, near Vadodara, India.
Acetaminophen injection had annual sales of USD 72 mn in the United States according to IQVIA data (IQVIA MAT Aug 2022).
The group now has 330 approvals and has so far filed over 428* ANDAs since the commencement of the filing process in FY 2003-04.
Shares of Cadila Healthcare Limited was last trading in BSE at Rs. 429.50 as compared to the previous close of Rs. 433.65. The total number of shares traded during the day was 76479 in over 3642 trades.
The stock hit an intraday high of Rs. 435.65 and intraday low of 428.00. The net turnover during the day was Rs. 33057971.00.
(*as of 30th June 2022)